Evotec and Almirall Nominate Dermatology Development Candidate

Evotec SE has announced the nomination of its first preclinical development candidate in collaboration with Almirall S.A. This marks a significant milestone in their partnership focused on developing treatments for immune-mediated inflammatory skin diseases. The joint effort has progressed from initial leads to preclinical nomination in just two years, showcasing their capability to expedite development timelines.

The collaboration combines Evotec's AI/ML-driven R&D capabilities with Almirall's dermatology expertise. The program aims to address high unmet medical needs in dermatology, particularly in immune-mediated conditions. Evotec will support the program toward IND submission through its INDiGO platform, ensuring a seamless transition to clinical readiness.

The successful nomination highlights the effectiveness of integrated, data-driven drug discovery processes and the potential benefits of collaborative partnerships in advancing medical innovation.